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Abstract
Objective: Investigating psychopathological profiles of transsexuals raises a very basic methodological question: are
control groups, which represent the biological or the phenotypic sex, most suited for an optimal evaluation of
psychopathology of transsexuals?
Method: Male-to-female (MtF) (n=52) and female-to-male transsexuals (FtM) (n=32), receiving cross-sex hormone
treatment, were compared with age matched healthy subjects of the same genetic sex (n=178) and with the same
phenotypic sex (n=178) by means of the Symptom Check List-90-Revisited instrument (SCL-90-R). We performed
analyses of covariance (ANCOVA) to test for group and sex effects. Furthermore, we used a profile analysis to
determine if psychopathological symptom profiles of transsexuals more closely resemble genotypic sex or phenotypic
sex controls.
Results: Transsexual patients reported more symptoms of psychopathological distress than did healthy control
subjects in all subscales of the SCL-90-R (all p<0.001), regardless of whether they were compared with phenotype or
genotype matched controls. Depressive symptoms were more pronounced in MtF than in FtM (SCL-90-R score 0.85
vs. 0.45, p = 0.001). We could demonstrate that FtM primarily reflect the psychopathological profile of biological
males rather than that of biological females (r = 0.945), while MtF showed a slightly higher profile similarity with
biological females than with biological males (r = 0.698 vs. r = 0.685).
Conclusion: Our findings suggest that phenotypic sex matched controls are potentially more appropriate for
comparison with the psychopathology of transsexual patients than are genetic sex matched controls.
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Introduction
Gender identity disorder (GID), also referred to as
transsexualism, is defined as a condition in which a person with
apparently normal somatic sexual differentiation is convinced
that he or she is actually a member of the opposite sex. This
conviction is accompanied by the unchangeable and irresistible
urge to live in the other sex, both physically and socially, and
by the wish to acquire the physical characteristics of the
desired sex to the fullest extent possible (according to ICD-10
[1] and DSM-IV criteria [2]). Biological causes of this
phenomenon have been discussed before [3-5].
Treatment protocols for patients with GID follow international
consensus statements [6] but vary considerably between
different countries and centers. Aside from sex reassignment
surgery, cross-sex hormone treatment has an important role to
play in acquiring the secondary sex characteristics of the
desired sex. In male-to-female- transsexuals, estradiol is
usually combined with an anti-androgen such as
spironolactone or cyproterone acetat for the control of
testosterone levels, while female-to-male transsexuals are
treated by either testosterone alone or combined with GNRH-
analogues in case of in the event of persistent bleedings [6].
The limited data on the long-term mortality of transsexuals
reveals that MtF transsexuals suffer from an increase of 51% in
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mortality compared to the general male population. This can
mostly be attributed to a six-fold increase in suicides which is
accompanied by a higher rate of psychiatric conditions [7-9],
and different risk behavior leading to HIV infections as well as
drug abuse [7,10]. In contrast, according to different studies,
female-to-male transsexuals do not implicitly have any higher
mortality risk, and may also lack an increased incidence of
psychiatric disorders [11] or suicidal intentions [7]. Nonetheless
there is no definite consent yet which may be the causes or
predictors of an increased risk of developing depressive or
anxiety disorders in the course of the treatment period, and
reliable markers identifying certain high-risk individuals in terms
of psychopathology are still lacking. This brings attention to the
methodological aspect of psychiatric assessment in the studies
discussed above, and what individual methodological
characteristics have to be kept in mind when interpreting the
data. Usually the results of transsexual patients are compared
to those of healthy age-matched control persons of the same
biological sex, or to the opposite transgender sex (FtM vs. MtF)
[11,12].
Aims of the study
The prevalence and extent of psychopathology such as
anxiety disorders and depression are highly sex-dependent
[13]. Therefore an approach comparing transgender individuals
to a group belonging to their biological sex rather than the sex
of their sexual identity, is questionable. We conducted a study
in hormone-treated transsexuals to assess their
psychopathology by means of self-reported symptoms of
mental disorders, and compared the results with matching
control groups, representing either the biological or the
phenotypic sex of transsexuals, with the aim of examining
which control group would be the best choice.
Materials and Methods
Ethics Statement
All participating subjects gave written informed consent, and
the study was approved by the local ethics committee of the
Ludwig Maximilians University in Munich (132-08).
Subjects
200 patients with the diagnosis “transsexualism” (GID)
according to ICD-10 criteria, and treated at the Endocrine
Outpatient Clinic of the Max Planck Institute of Psychiatry in
Munich between January 1996 and December 2007, were
identified through the electronic database of the Institute and
consecutively invited to participate in this study (MtF = 118,
FtM = 82) in 2009. Additionally, the clinicians and
psychotherapists participating in regional quality circles for
transsexualism assisted in terms of contacting some of the
patients. All transsexuals underwent hormone replacement
therapy in the endocrine outpatient clinic of the Max Planck
Institute of Psychiatry.
Our final sample consisted of 89 transsexual patients (MtF =
57, FtM = 32) aged 18 years or older, corresponding to a
response rate of 44% (MtF) and 39% (FtM), respectively, a
difference which was not significant. One MtF patient was
excluded from the analysis due to ambiguous information about
the biological sex. Four patients were excluded because they
didn’t receive hormone replacement therapy. Finally we
enrolled 84 transsexual patients (52 MtF, 32 FtM) in the study.
As a control sample, we selected 336 subjects with a
negative lifetime history of mental axis I disorders, including
any gender identity disorders, from a large cohort, the so called
Munich Antidepressant Response Signature (MARS) control
sample [14]. For the 52 MtF transsexual patients we matched,
according to age, 104 male (same genetic sex, genetic match)
and 104 female controls (same phenotypic sex, phenotypic
match). For the 32 FtM transsexual patients we matched 64
female (genetic match) and 64 male control individuals
(phenotypic match).
Measures
Questionnaires including general questions on the course of
the sexual transition phase, treatment, social background and
sexuality had been evaluated previously [11]. The evaluation in
terms of psychopathology was done by means of the Symptom
Check List-90-Revised (SCL-90-R) inventory. The SCL-90-R is
a self-report questionnaire for assessing a broad range of
psychopathology symptoms [15] and has been used earlier in
this context [11]. It is composed of 90 items with regard to
symptoms for which the subject rates on a five-point Likert
scale of 0 (none at all) to 4 (extremely), the rate of congruence
of the symptom in the last seven days. The SCL-90-R consists
of 9 primary symptom dimensions: somatization (SOM),
obsessionality (O-C), interpersonal sensitivity (IS), depression
(DEP), anxiety (ANX), hostility (HOS), phobic anxiety (PHOB),
paranoid ideation (PAR), and psychoticism (PSY) as well as
the Global Severity Index (GSI) that indicates the general level
of psychological distress. The German Version of the
questionnaire by Franke was applied [16].
Statistical analysis
Analyses were processed using PASW statistical software
(release 18.0.0, SPSS Inc., Chicago, USA). The level of
significance was set to be p= .05. We calculated Cohen’s f as
the effect size measure. According to Cohen’s guidelines
(1988), we categorized effects as small (f< .10), medium (f ≥ .
25), and large (f ≥ .40). Mean group differences in terms of
demographic and clinical variables were analyzed using the
Student’s t-test in the case of quantitative variables, and
Fisher’s exact tests with regard to dichotomous variables.
We performed analyses of covariance (ANCOVA) to
compare transsexual patients with their matched healthy
controls (HC). The factors “group” (TS or healthy controls) and
“sex” (male, female) were tested for their effects on the
SCL-90-R subscales (SOM, O-C, I-S, DEP, ANX, HOS, PHOB,
PAR, PSY, GSI). Two separate ANCOVAs were performed,
one to investigate differences between transsexuals and
matched healthy controls with the same genetic sex (sex_gen),
and a second with respect to controls with the same phenotypic
sex (sex_phen). Age was included as a covariate in these
analyses.
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Univariate ANCOVA was used to determine the differences
between MtF and FtM transsexuals in the SCL-90-R symptom
subscales. We analyzed every SCL-90-R subscale regarding
differences in the factor sex (MtF, FtM). In this analysis, we
added age, depression diagnosis, sex reassignment surgery,
age at which the transsexual patients discovered their
transsexuality and the duration of hormone therapy in years, as
covariates.
To elucidate whether the symptom profile of transsexual
patients resembles the profile of the control group of the same
genetic or the same phenotypic sex, we performed a profile
analysis of the total SCL-90-R outcome using Pearson
correlations as proximity measure. Pairwise correlations were
calculated between transsexuals (MtF, FtM) and both healthy
control groups (phenotypic match, genotypic match), and
averaged after Fisher-Z transformation to a general proximity
score of psychopathological symptoms.
Results
Patient characteristics
In the study, the mean age of MtF transsexual patients was
47.96 (SD 11.69) and 32.38 (SD 7.75) in FtM transsexuals (p<.
001). The age at onset of the gender identity disorder was
significantly higher in MtF (12.78, SD 9.79) than in FtM (8.81,
SD 5.22) (p=.042). The average duration of hormone
replacement therapy was 7.05 years (SD 8.01) in MtF
transsexuals and 5.46 years (SD 4.50) in FtM transsexuals,
which was not statistically significant. Twenty-one subjects in
the FtM group had undergone complete sex reassignment
surgery (65.6%), similar to the MtF group with 37 (66%). The
majority of MtF (48.1%) received transdermal estrogens for
hormonal therapy, while most of FtM were treated by
intramuscular testosterone formulations (87.5%) (Table 1).
There was no significant difference in terms of the highest
education level or the current employment situation. Fourteen
(43.8%) of the FtM transsexuals lived in a committed
relationship in comparison to eighteen in the MtF group
(34.6%), though the difference was not significant.
In the group of MtF transsexuals, seven patients reported a
diagnosis of depression in their history (13.5%) compared to
five patients (15.6%) in FtM transsexuals (p=.761) (Table 1,2).
Univariate analysis of SCL-90-R subscales in
transsexuals (MtF vs. FtM)
By comparing MtF and FtM transsexuals in the mean with
regard to SCL-90-R subscales, we found a different distribution
of psychopathology (see Table 2). Significant sex differences
occurred in the subscales obsessionality (p=.015), depression
(p=.001), phobic anxiety (p=.007), paranoid ideation (p=.022)
and also in the general psychopathological scale GSI (p=.028).
The strongest effect was seen in the subscale depression (f=.
395), which could be categorized as a medium effect. MtF
transsexuals reported significantly more symptoms of
depression than did FtM transsexual patients, and also had
significantly higher mean scores in the subscales
obsessionality, phobic anxiety, paranoid ideation, and in the
overall psychopathology index GSI.
Univariate analysis of SCL-90-R subscales in
transsexuals compared to healthy controls (TS vs. HC)
The mean scores of the SCL-90-R subscales are shown in
Table 2, with transsexual patients divided into MtF and FtM,
and the control groups divided into genotype (sex_gen) and
phenotype (sex_phen) matched healthy controls. The SCL-90-
R profiles of the MtF and FtM transsexuals compared to their
respective control groups of the same genetic or phenotypic
sex, are presented in Figures 1a and 1b.
First, we analyzed the effects of group (transsexual vs.
control) and sex (genetic men vs. genetic women) in
transsexual patients, and matched healthy controls with the
same genotypic sex (sex_gen). We also tested for the
interaction effects in terms of group and sex. Transsexual
patients had significantly higher mean scores in all SCL-90-R
subscales compared to healthy controls, which was significant
at p<.001 for all psychopathology subscales. Regarding sex
differences in the analysis with genetic matches, we found
significant main effects of sex in the following SCL-90-R-
subscales: depression (p=.013), phobic anxiety (p=.001) and
paranoid ideation (p=.011). The largest sex effect (f=.242) was
found for the subscale phobic anxiety. There was an interaction
effect in terms of group x sex_gen (p=.001) for the scale
depression, with MtF patients reporting more severe
depressive symptoms than FtM, as well as male and female
genotype matched controls (see Table 3).
Next, we repeated the same analysis after exchanging the
control group with healthy controls, which were matched for the
phenotypic sex of the transsexual patients (sex_phen). Again,
we found significant group differences in all SCL-90-R
subscales (p<.001), with transsexual patients reporting
significantly more psychopathology symptoms than the
phenotype matched healthy control group. Significant main
effects of sex appeared for the following SCL-90-R subscales:
IS (p=.027), depression (p<.001), hostility (p=.035), phobic
anxiety (p=.001), paranoid ideation (p=.006), and for the
general psychological distress index GSI (p=.010). The
strongest sex effect (f=.527) was found for the subscale
depression, which could be categorized as a large effect. There
was a significant interaction effect with regard to group x
sex_phen (p=.013) in this subscale. Again, MtF patients
reported the most severe depressive symptoms, higher than
those observed in FtM, as well as in female and male subjects
of the phenotype-matched controls (see Table 3, Figures 1a,
b). There was no significant difference regarding any subscale
of the SCL-90-R between MtF taking additional antiandrogens
and those who did not (data not shown).
Profile analysis
Next, we conducted a profile analysis to determine whether
psychopathological symptom profiles resemble the profile of
controls with the same genotypic or phenotypic sex. Separate
profile correlations between TS (MtF, FtM) and healthy controls
of the same genotypic or phenotypic sex were conducted
across all SCL-90-R subscales. FtM showed the closest
proximity with the phenotype-matched male control group (r=.
945), but also showed a high resemblance with the genotype-
matched female control group (r=.895). Also MtF transsexuals
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had considerable, but smaller profile proximity with both control
groups, with an average correlation of r=.685 with the
genetically-matched control group of males and of r=.698 with
the phenotypically-matched female control group.
Discussion
In this study, we could show that transsexual patients
present with significantly higher mean scores in all
psychopathology subscales of the SCL-90-R, regardless of
whether they are compared with phenotype- or genotype-
matched controls. The effects ranged between a medium and a
large effect size. This suggests an increased burden of
psychopathological distress in transsexual patients. In
particular, depressive symptoms were more pronounced in MtF
than in FtM, which is in accordance with the literature.
Furthermore, we could demonstrate that FtM primarily reflect
the psychopathological profile of biological males rather than
Table 1. Demographics: transsexualism, education, profession.
 TS MtF TS FtM
 N=52 N=32
 Mean SD mean SD pa
duration hormone therapy (years) 7.05 8.01 5.46 4.50 n.s.
age of onset GID 12.78 9.79 8.81 5.22 .042
 N % n % pb
depression diagnosis 7 14.5 5 15.6 n.s.
hormone-therapy      
oral estrogens 13 25.0 - -  
transdermal estrogens 25 48.1 - -  
intramuscular estrogens 8 15.4 - -  
unknown route of application 6 11.5 - -  
additional antiandrogens 17 23    
intramuscular testosterone - - 28 87.5  
transdermal testosterone - - 3 9.4  
unknown route of application - - 1 3.1  
sex reassignment surgery     n.s.
no surgery performed 16 30.1 8 25  
complete reassignmentc 34 65.4 21 65.6  
incomplete reassignment 2 4.5 3 9.4  
orchidectomy only 1     
breast augmentation only 1     
mastectomy only   2   
hysterectomy only   1   
profession      
student 3 5.8 6 18.8  
working full time 29 55.8 19 59.4 n.s.
working part time 4 7.7 1 3.1  
retired 6 11.5 1 3.1  
Unemployed (seeking employment) 7 13.5 2 6.3  
Unemployed 3 5.8 2 6.3  
education status      
no graduation 2 3.8 0 0.0  
secondary school 17 32.7 6 18.8 n.s.
intermediate school 9 17.3 13 40.6  
technical school 8 15.4 2 6.3  
higher education 15 28.8 10 31.3  
committed relationship 18 34.6 14 43.8 n.s.
Note: TS MfF = male-to-female transsexuals; TS FtM = female-to-male transsexuals; GID = Gender Identity Disorder; SD = standard deviation; n.s. = not significant on a
significance level of p<.05; SD = standard deviation.
a p-value are from Students t-test
b p-value are from Chi-square test or Fisher’s exact test (depression diagnosis variable)
c in FtM: hysterectomy, ovariectomy, mastectomy, phalloplasty; in MtF bilateral orchidectomie, penectomy, breast augmentation if necessary, vaginoplasty, vulvoplasty
doi: 10.1371/journal.pone.0078469.t001
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that of biological females, while MtF showed slightly higher
profile similarities with biological females rather than with
biological males.
By performing separate analyses to find the proper control
group for transsexual patients, we could show that group
effects were present in both comparisons, but sex effects
differed, depending on the genetic or phenotypic sex of the
controls. Both comparisons revealed sex effects for the
SCL-90-R subscales depression, phobic anxiety and paranoid
ideation, with larger effect sizes observed in the second
analysis, when transsexual patients were matched with
controls of the same phenotypic sex. In addition to these
effects, women scored higher in the subscale obsessionality,
and the general psychopathological scale GSI in the second
analysis. Both analyses also revealed a group by sex
interaction for the depression subscale, with MtF transsexuals
reporting most depressive symptoms. This interaction effect
was less pronounced in the second analysis as a result of the
larger difference between FtM and phenotypic sex-matched
controls regarding depressive symptoms.
Though there are several studies on psychopathology in the
transgender population [17-19], so far little attention has been
paid to the sex-specific rates of psychiatric disturbances among
biological men and women [20]. However, when aiming to
investigate psychopathological differences in the transgender
population, findings depend on the selection of the right control
group. Due to their special status among the sexes,
transsexuals can theoretically either be compared to a control
group matched for the same genetic or for the same
phenotypic sex.
Therefore, to evaluate the similarity of symptom profiles
between patients and controls, we performed a profile analysis
across all SCL-90-R subscales. The best profile similarity with
FtM was seen in the male control group (matched for the
phenotypic sex, r=.945). However, similarity with the female
control group (matched for the genetic sex) could also be
shown, albeit to a lower degree (r=.895). Regarding the MtF
group, similarities with the phenotypically (r=.698) as well as
with the genetically matched control group (r=.685) were both
less pronounced. This might be explained by the more
advanced age of the MtF group and the matched controls,
resulting in an attenuated variability, especially, within the
control group. However, we again observed slightly higher
similarities between MtF and phenotypically-matched controls.
While the marginal difference in the similarity scores between
MtF patients and both control groups hinders a definite
statement about the right control group in terms of providing
the optimal psychopathological comparability, it is interesting
that the similarity with the phenotypic sex-matched controls
was higher for both patient samples, MtF and FtM. This is in
line with the finding of more pronounced sex typical effects on
the SCL-90-R subscales when transsexual patients are
analyzed in combination with phenotypic sex-matched controls,
suggesting that the expected sex differences become more
visible in combination with this control group.
The results in this study are in accordance with earlier
findings on the high prevalence of depressive symptoms in the
transgender population [21,22]. However, in comparison with
the results from Haraldsen et al. (2000), the group difference
between patients and controls in our study was larger [11]. This
may be partially attributed to the fact that our control samples
Table 2. Demographics: SCL-90-R mean scores in TS and HC.
 TS MtF TS FtM HC men gen HC women HC men HC women
    gen phen phen
 n=52 n=32 n=104 n=64 n=64 n=104
 mean SD mean SD mean SD mean SD mean SD mean SD
age 47.96 11.69 32.38 7.75 48.27 10.91 32.77 7.92 48.16 11.40 33.44 7.20
SCL-90-R             
SOM .51 .47 .56 .50 .31 .34 .34 .33 .22 .18 .33 .30
O-C .64 .64 .58 .56 .31 .39 .32 .31 .22 .26 .29 .31
IS .73 .76 .59 .77 .28 .43 .24 .23 .18 .23 .27 .29
DEP .85 .76 .45 .55 .23 .33 .31 .40 .17 .23 .26 .28
ANX .40 .48 .36 .51 .15 .31 .19 .27 .10 .18 .18 .22
HOS .49 .52 .46 .66 .20 .39 .23 .29 .13 .18 .21 .27
PHOB .40 .68 .19 .42 .08 .23 .04 .09 .03 .07 .07 .13
PAR .72 .83 .49 .66 .28 .43 .22 .27 .15 .23 .27 .35
PSY .30 .36 .25 .35 .12 .26 .08 .13 .06 .11 .12 .18
GSI .58 .51 .45 .48 .23 .28 .24 .22 .15 .14 .24 .20
Note: TS = transsexuals; HC = healthy controls; TS MtF = male-to-female transsexuals; TS FtM = female-to-male transsexuals; HC men gen = matched healthy male
controls of the same genetic gender; HC women gen = matched healthy female controls of the same genetic gender, HC men gen = matched healthy male controls of the
same phenotypic gender; HC women gen = matched healthy female controls of the same phenotypic gender, SD = standard deviation. SCL-90-R symptom dimensions:
SOM = somatization, O-C = obsessionality, IS = interpersonal sensitivity, DEP = depression, ANX = anxiety, HOS = hostility, PHOB = phobic anxiety, PAR = paranoid
ideation, PSY = psychoticism, GSI= Global Severity Index.
doi: 10.1371/journal.pone.0078469.t002
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Figure 1.  Profiles of SCL-90-R subscales in FtM and MtF transsexuals and genoptype/phenotype matched healthy controls
(HC).  FtM present with high scores in most SCL90 subscales. Proximity analysis revealed that profiles of FtM best resembled those
of the phenotype matched male control group, but also high resemblance with the genotype matched female control group was
seen (a). MtF present with high scores in different SCL90 subscales, most prominent in the subscale depression. MtF transsexuals
had considerable, but smaller profile proximity with both control groups (b).
Note: TS = transsexuals; HC = healthy controls; TS MtF = male-to-female transsexuals; TS FtM = female-to-male transsexuals; HC
men gen = matched healthy male controls of the same genetic gender; HC women gen = matched healthy female controls of the
same genetic gender; HC men gen = matched healthy male controls of the same phenotypic gender; HC women gen = matched
healthy female controls of the same phenotypic gender;, SCL-90-R symptom dimensions: SOM = somatization, O-C =
obsessionality, IS = interpersonal sensitivity, DEP = depression, ANX = anxiety, HOS = hostility, PHOB = phobic anxiety, PAR =
paranoid ideation, PSY = psychoticism, GSI= Global Severity Index. SD = standard deviation.
doi: 10.1371/journal.pone.0078469.g001
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were pre-selected for the absence of any mental disorder,
while other studies used control samples of the general
population [11].
Our findings also correspond well with the appearance of
higher SCL-90-R psychopathology scores in female subjects
[15,16]. The most consistent sex effect appeared with regard to
the SCL-90-R subscale, depression. Sex differences could be
observed between transsexuals and both control groups, and
the sex by group interaction pointed to the high depression
score observed in MtF transsexuals, who reported distinctly
more depressive symptoms than FtM transsexuals. Interpreting
these effects, one has to consider that although MtF
transsexuals reported high values in the depression subscale,
there were no differences between MtF and FtM in terms of
clinically diagnosed depression. Others, however, have
reported a higher prevalence of mental health problems in FtM
than in MtF [19].
The discrepancy between SCL-90-R psychopathology
scores and the history of clinical diagnosis of depression, may
be explained by the way the depression diagnosis was
obtained, which was from chart analysis and self-reports. This
might have led to an underestimation of the true prevalence in
our sample.
In summary, it appears that within the transsexual
population, MtF have a higher burden of depressive symptoms
compared to healthy controls, but also compared to FtM
transsexuals. This is in agreement with current research
findings [8,23]. Asscheman et al. [7] demonstrated that MtF
under cross-sex hormone treatment had a 51% higher mortality
risk, mainly due to an increased suicide rate, than the general
population. In FtM this increase was not observed. Though the
increase in suicide rates in these patients is certainly
multifactorial, the most obvious reason for this observation is
an increased prevalence of depression. There are a variety of
factors which may explain the higher rate of psychiatric
conditions in MtF in comparison to FtM. These may be related
to social factors such as the acceptance of this disorder by
society [24] or the feeling of unattractiveness related to an
incongruent body image [25]. Especially in male-to-female
transsexuals, it has to be taken into account that if cross-sex
hormonal therapy is not induced prior to puberty, individuals
have male facial characteristics and male voice patterns which
leads to a stigmatization of the individual [26]. However, a
satisfying explanation for the difference between MtF and FtM
in terms of psychopathology is still pending, and so far remains
speculative. It may be attributed, for example, to the fact that
MtF feel more stigmatized than FtM [25], potentially as result of
a low social acceptance of MtF in the general population [27].
While the initiation of cross-sex hormone treatment, apart from
genital characteristics, will lead to an almost perfect male
phenotype in FtM, MtF often have to struggle with stigmata
such as a deep voice and persistent male facial bone
characteristics, clearly identifying them as being born a
biological male [28].
Since the initiation of hormone treatment has been reported
to have a fundamental impact on general well-being and mood
[9], we decided for reasons of sample homogeneity, and to
increase the statistical power, only to include those in our
analysis who were already receiving cross-sex hormone
treatment at the time of the evaluation.
Although sex steroids are widely involved in mood regulation
[29] and may at least partly account for differences in gender
Table 3. ANCOVA p-values and effect sizes for different SCL90-scores.
 Matched for genetic gender: sex_gen  Matched for phenotype gender: sex_phen
 main effect main effect interaction  main effect main effect interaction
 group gender group x  group gender group x
 (TS vs. HC) (male vs. gender  (TS vs. HC) (male vs. gender
  female)    female)  
 p f p f p f  p f p f p f
SOM <.001 .248 .346 - .913 -  <.001 .392 .845 - .125 -
O-C <.001 .295 .183 - .562 -  <.001 .451 .133 - .984 -
IS <.001 .348 .055 - .541 -  <.001 .477 .027 .153 .751 -
DEP <.001 .360 .013 .172 .001 .225  <.001 .287 .000 .527 .013  
ANX <.001 .264 .436 - .448 -  <.001 .394 .108 - .659 -
HOS <.001 .274 .196 - .651 -  <.001 .424 .035 .144 .569 -
PHOB <.001 .291 .001 .242 .115 -  <.001 .363 .001 .227 .085 -
PAR <.001 .305 .011 .176 .238 -  <.001 .417 .006 .190 .409 -
PSY <.001 .303 .225 - .965 -  <.001 .410 .173 - .912 -
GSI <.001 .366 .094 - .189 -  <.001 .540 .010 .180 .673 -
SOM <.001 .248 .346 - .913 -  <.001 .392 .845 - .125 -
O-C <.001 .295 .183 - .562 -  <.001 .451 .133 - .984 -
Note: sex_gen = age matched healthy controls of the same genetic gender; sex_phen = age matched healthy controls of the same phenotypic gender; TS = transsexuals;
HC = healthy controls. SCL-90-R symptom dimensions: SOM = somatization, O-C = obsessionality, IS = interpersonal sensitivity, DEP = depression, ANX = anxiety, HOS =
hostility, PHOB = phobic anxiety, PAR = paranoid ideation, PSY = psychoticism, GSI= Global Severity Index. p = p-value, f = Cohen’s f effect size, reported if p<.05.
doi: 10.1371/journal.pone.0078469.t003
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prevalences of mood disorders [30], their exact impact on the
psychopathology in transsexuals, for example by direct
biological effects on brain functioning and neurotransmitter
metabolism [31], remains an object of speculation.
Low testosterone levels or hypogonadism has been
repeatedly associated with mood disturbances in biological
males [32]. Correspondingly, in MtF, negative effects on mental
health may be exerted by complete androgen withdrawal.
However, a recent study demonstrated that cross-sex
hormone treatment has beneficial effects in terms of lower
levels of anxiety and depressive symptoms in FtM as well as in
MtF [9]. In further studies it would therefore be interesting to
see which mechanisms have an effect on mood in MtF
compared to hypogonadal men. However, such features as
estrogen substitution in MtF, and an especially low
testosterone level, often being lower than that usually seen in
premenopausal biological females [33], may interfere with
result interpretation.
In addition, there are also fundamental gender differences
regarding social interactions and partnership integrity, further
influencing psychological outcome measures [34]. Moreover,
socioeconomic aspects such as lower income and less
qualified employment on the part of MtF seem to have a role to
play in this context [19]. Indeed, in our sample, unemployment
tended to be more common among MtF than among FtM.
However, this different was not statistically significant.
There have also been reports that mental health improves
following sex reassignment surgery [12,35,36]. One reason
might be that individuals feel less insecure and unattractive
[25]. However, in our study, we found no difference between
those who had already undergone sex reassignment and those
who had not in terms of any subscale of psychopathology.
Therefore sex reassignment surgery doesn’t seem to be a
major contributor to psychosocial well-being in our transsexual
sample. This is in accordance with a recent systematic review
and meta-analysis which concluded that although many
subjects benefit from sex reassignment, there is also evidence
of higher psychiatric morbidity and suicide rates following the
procedure [36].
To the best of our knowledge, this is the first study
investigating in detail the psychopathology of transsexuals and
healthy controls assessed by SCL-90-R divided into phenotype
and genotype matched subjects. In summary, we could
demonstrate that transsexual patients report more symptoms of
psychopathological distress than healthy control subjects,
regardless of whether they are compared with phenotype or
genotype matched controls. Symptoms of depression were
increased in MtF transsexuals, and they are also more
burdened in terms of other aspects of psychopathology than
FtM. The proper control group for FtM transsexuals in terms of
their profile similarity with regard to psychopathological
symptoms, seems to be age-matched men rather than women,
supporting the view that phenotypic sex-matched controls are
the more appropriate choice. While the differences in profile
similarity were less pronounced between MtF and both age-
matched control groups, the overall observed sex effects are
additionally supportive for selecting phenotypic sex -matched
controls as the appropriate comparison group for evaluating
psychopathology in transsexual patients under hormone
replacement therapy.
Strength and limitations
The strength of this single-center study is its well-defined
study groups. However, the choice of the control samples can
either be regarded as a strength or a limitation in this context.
On the one hand, all controls were initially selected as healthy
control groups for a depression sample and, therefore, report
low scores in SCL-90-R subscales and GSI in comparison to
the general population [37]. This might explain the large group
effects seen in our study. On the other hand, the homogeneity
of our control group with regard to mental health also allowed
us to investigate the psychopathological profiles of our
transgender subjects isolated from potential confounding
factors. A limitation is the higher age of the MtF transsexuals,
who were on average 16 years older than the FtM group. The
older age of the age-matched control groups resulted in a
reduced variability in terms of psychopathology scores, thus
reducing the power to identify profile similarities between MtF
and genetic or phenotypic sex-matched controls. Therefore, it
would be interesting to repeat the analysis of
psychopathological profiles in a younger sample of MtF.
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